Steglatro - (5 mg and 15 mg ; Tablets)

Generic Name	Ertugliflozin	Innovator	Merck
Dosage	5 mg and 15 mg ; Tablets	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	Less Than 5	Generic Launches	None
Indication	STEGLATRO is a sodium glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*********	*** / *********	**** **, ****	*******	******** ************	******* *** **** *** *** ****
******	*** / *********	**** **, ****	*******	********	******* *** **** *** *** ****
****** ******	*** / ***	**** **, ****	*******	********* ********	******* *** **** *** *** ****

Chronology Of Events